Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CMBI Cuts GIANT BIOGENE (02367.HK) TP to $53.89, Rating Buy
Recommend 7 Positive 6 Negative 4 |
||||
|
||||
|
GIANT BIOGENE (02367.HK) faced sales pressure during the Double 11 period, primarily due to the sales miss from broadcasting, CMB International's research report indicated. On one hand, the company actively adjusted its channel strategy, while on the other, it reflected the overall competitive pressure in the industry. However, the management maintained strategic focus amidst industry changes, preserving price levels and consumer experience, and increased the proportion of self-broadcast channels, laying the foundation for long-term growth. Given the short-term pressure on Comfy during Double 11, CMB International lowered the company's revenue growth rate for 2025 and 2026 to a decline of 3.5% and a rebound of 13.6%. Based on the DCF model, the target price was chopped to HKD53.89, with the Buy rating maintained. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
